Black Diamond Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | — | — | — |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M |
| Operating expenses | $57.5M | $78.8M | $86.5M | $92.8M | $126.9M |
| Cash from operations | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M |
| Capital expenditure | — | $0 | $33,000 | $192,000 | $2.7M |
| Free cash flow | — | -$62.3M | -$66.8M | -$85.3M | -$102.9M |
| Impairments | $7.3M | $0 | — | — | — |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M |
Shares outstanding 57.3M · Free float 65.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.